South Korea Benign Prostatic Hyperplasia Treatment Market Size, Share, Growth, and Industry Analysis, By Treatment Type (Pharmacological treatmentAlpha-blockersTamsulosinSilodosinAlfuzosinDoxazosinOther alpha-blockers5-alpha reductase inhibitors (5-ARI)DutasterideFinasterideCombination therapyAlpha-blockers + 5-arisAlpha-blockers + pde5 inhibitorsPhosphodiesterase-5 inhibitors (pde5 inhibitors)Herbal and other drugs, Surgical treatmentTransurethral resection of the prostate (TURP)Transurethral incision of the prostate (TUIP)Open prostatectomyLaser therapyHolmium laser enucleation of the prostate (HOLEP)Photoselective vaporisation of the prostate (PVP), Minimally invasive proceduresUrolift systemRezūm water vapour therapyProstatic artery embolisationMicrowave thermotherapyTransurethral needle ablation (TUNA), Other treatmentsLifestyle modificationsWatchful waiting / active surveillance), By End Use (Hospitals, Clinics, Ambulatory surgical centres, Specialty urology centers) and Forecast, 2026-2034

South Korea Benign Prostatic Hyperplasia Treatment Market Trends

Rapid Adoption of Cutting-Edge Minimally Invasive Technologies

The South Korean BPH treatment market is witnessing rapid adoption of cutting-edge minimally invasive technologies, driven by the country's technological leadership and high patient expectations for advanced care. Technologies such as Rezūm water vapor therapy, UroLift, and various laser-based procedures are being rapidly integrated into clinical practice across major urology centers. South Korean urologists are known for their early adoption of innovative technologies, and the country serves as a regional hub for clinical trials and technology evaluation, accelerating the introduction of new BPH treatment modalities.

Focus on Preservation of Sexual Function and Quality of Life

There is a pronounced trend towards treatments that preserve sexual function and maintain quality of life in the South Korean BPH treatment market. South Korean patients are increasingly prioritizing therapies that minimize the risk of ejaculatory dysfunction, erectile dysfunction, and other side effects associated with traditional treatments. This patient-centric trend is driving demand for minimally invasive procedures with favorable sexual function preservation profiles and supporting the development of novel pharmacological agents with improved tolerability profiles.

Market Dynamics

South Korea Benign Prostatic Hyperplasia Treatment Market Drivers

Rapid Population Aging and Increasing BPH Prevalence

The primary driver for the South Korean BPH treatment market is the country's exceptionally rapid population aging, with South Korea having one of the fastest aging rates among OECD countries. BPH prevalence increases dramatically with age, affecting approximately 50% of men over 50, 60% over 60, and up to 90% of men over 80 years of age. As South Korea's population continues to age rapidly, with the proportion of men aged 65 and older projected to exceed 30% by 2034, the absolute number of men requiring BPH treatment is expected to increase substantially, driving demand across all treatment modalities.

South Korea Benign Prostatic Hyperplasia Treatment Market Restraints

Reimbursement Limitations and Healthcare Cost Pressures

The market faces significant restraints from reimbursement limitations and healthcare cost pressures within the South Korean National Health Insurance Service (NHIS) system. While basic BPH treatments are well-covered, reimbursement for newer and more expensive device-based therapies can be limited or subject to strict criteria. These reimbursement constraints can slow the adoption of innovative technologies and limit market growth for premium-priced treatments, requiring manufacturers to demonstrate clear cost-effectiveness.

South Korea Benign Prostatic Hyperplasia Treatment Market Opportunities

Expansion of Medical Tourism and Regional Clinical Trials

Significant opportunities exist in the expansion of medical tourism and regional clinical trial activities in South Korea. The country's reputation for advanced urological care and technological innovation attracts patients from across Asia, particularly from neighboring countries seeking high-quality BPH treatment. Additionally, South Korea's robust clinical research infrastructure and rapid patient recruitment capabilities make it an attractive location for clinical trials of new BPH therapies, presenting opportunities for manufacturers to generate local data and gain early market access.

Challenges in South Korea Benign Prostatic Hyperplasia Treatment Market

Intense Competition and Price Pressure

The market faces ongoing challenges from intense competition and price pressure in the South Korean healthcare market. The pharmaceutical segment is characterized by strong competition from both multinational and domestic generic manufacturers, leading to significant price erosion for off-patent medications. Similarly, the device segment faces increasing competition from both established players and new entrants, putting pressure on pricing and margins, and requiring manufacturers to continuously innovate to maintain market share.

South Korea Benign Prostatic Hyperplasia Treatment Market Segmentation Analysis

The South Korean BPH treatment market is segmented by Type, Application, and Distribution Channel, providing comprehensive insights into the industry structure. By type, Drugs dominate with approximately 46% market share, reflecting strong physician preference for pharmacological management and established treatment pathways. In terms of application, Monotherapy represents both the largest and fastest-growing segment, accounting for approximately 58% of the market. Hospital Pharmacies constitute the dominant distribution channel, accounting for over 48% of the market, driven by hospital-based treatments and the availability of specialist urology services.

By Type

Drugs: This segment dominates the South Korean market, accounting for approximately 46% of the total market share. Pharmacological agents include alpha-blockers (tamsulosin, alfuzosin), 5-alpha reductase inhibitors (finasteride, dutasteride), phosphodiesterase-5 inhibitors (tadalafil), and combination therapies. Annual prescriptions exceed 2.2 million units across South Korea, with technical specifications including advanced formulation types and consistent clinical effectiveness.

Devices (Minimally Invasive Therapies): The fastest-growing segment, accounting for approximately 29% of the market, includes Rezūm water vapor therapy, UroLift, and various laser-based technologies. Annual procedure volumes exceed 55,000 across South Korea, with technical specifications including advanced delivery systems, precise energy control, and favorable safety profiles.

Surgery: This segment accounts for approximately 25% of the market and includes transurethral resection of the prostate (TURP), laser therapies (HoLEP, GreenLight), and prostatectomy. Annual procedure volumes exceed 48,000 across South Korea, with technical specifications including energy source, tissue ablation efficiency, and complication profiles.

By Application

Monotherapy: The dominant application segment, accounting for approximately 58% of the market, involves treatment with a single pharmacological agent or procedure. Annual treatment regimens exceed 1.2 million patient-years across South Korea, with growth projections of 8.0% annually, driven by strong physician preference and established clinical protocols.

Combination Therapy: The fastest-growing application segment, accounting for approximately 42% of the market, involves the simultaneous use of multiple therapeutic approaches. Annual treatment regimens exceed 0.9 million patient-years, with growth projections of 8.5% annually, driven by increasing clinical evidence and growing awareness of combination therapy benefits among South Korean urologists.

South Korea Benign Prostatic Hyperplasia Treatment Market Outlook

 The Seoul Capital Area holds the largest share of the South Korean BPH treatment market, accounting for approximately 45-48% of the national total, with a market valuation exceeding USD 120 million in 2026. Key contributions come from Seoul, Incheon, and Gyeonggi Province, where the highest concentration of leading hospitals and urology centers is located. The pharmaceutical segment represents the dominant treatment modality, accounting for approximately 46% of regional demand, followed by devices at 30% and surgery at 24%.

Gyeongsang is the fastest-growing region in South Korea, exhibiting a CAGR of 8.5%, fueled by increasing healthcare investments and growing aging population in cities like Busan, Daegu, and Ulsan. Key contributions come from the region's industrial cities with large elderly populations, with a balanced sector split of approximately 45% pharmaceuticals, 30% devices, and 25% surgery.

Jeolla Region is projected to reach USD 68.5 million by 2034, growing at a CAGR of 8.2%, supported by improving healthcare infrastructure and increasing elderly population in the southwestern part of the country. Key cities including Gwangju and Jeonju are emerging as regional healthcare hubs, with the pharmaceutical segment accounting for approximately 47% of regional demand, followed by devices at 29% and surgery at 24%.

Chungcheong contributes approximately 10-12% of the South Korean market, with steady growth driven by an aging population and established healthcare facilities. Key contributions come from Daejeon and Sejong, with the pharmaceutical segment accounting for approximately 46% of regional demand, followed by devices at 28% and surgery at 26%.

Top players in South Korea Benign Prostatic Hyperplasia Treatment Market

• Yuhan Corporation
• Hanmi Pharmaceutical Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd.
• Dong-A ST Co., Ltd.
• JW Pharmaceutical Corporation
• Korea United Pharm Inc.
• Boryung Pharmaceutical Co., Ltd.
• Bukwang Pharmaceutical Co., Ltd.
• Pfizer Inc. (South Korea Operations)
• AstraZeneca plc (South Korea Operations)
• Bayer AG (South Korea Operations)
• Boston Scientific Corporation (South Korea Operations)
• Medtronic plc (South Korea Operations)
• Olympus Corporation (South Korea Operations)
• Karl Storz SE & Co. KG (South Korea Operations)